Efficacy Outcomes of Repotrectinib in Patients with NTRK-positive Solid Tumours By Ogkologos - February 10, 2026 278 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRIDENT-1 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Some People with Rectal Cancer Can Skip Radiation Before Surgery July 19, 2023 New chemotherapy-free treatment for bowel cancer made available in Scotland September 14, 2021 2021 ASCO Annual Meeting Research Round Up: Advances in Treating Brain... September 30, 2021 Trastuzumab May Improve Survival in Women with Rare Endometrial Cancer August 13, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib Workout Wednesday – Upper Body Stretches Adjuvant Pembrolizumab Continues to Demonstrate a Clinically Meaningful DMFS Benefit in... Pesticide Usage, in Particular of Picloram, Associated with Early Onset Colorectal...
